Pelthos (PTHS) Q2 2026 earnings review
Zelsuvmi Adoption Accelerates, But Milestones and Write-offs Highlight Growing Pains
Pelthos Therapeutics delivered a standout quarter on the top line, with Zelsuvmi net product revenue accelerating 45% sequentially to $15.4 million. The core commercial metrics are incredibly strong: dispensed units jumped 48% quarter-over-quarter to 11,925. However, this rapid growth came with operational friction. SG&A spiked 31% sequentially due to a $5.3 million non-recurring sales milestone, and COGS was hit by a $0.9 million API inventory write-off. While the Adjusted EBITDA loss narrowed to $5.7 million, the company's cash position of $24.2 million leaves little margin for error as it prepares for the upcoming Xepi and Xeglyze launches.
🐂 Bull Case
Zelsuvmi generated $42.3 million in its first four quarters, surpassing the 30,000 unit milestone shortly after Q2 end. The 48% sequential unit growth proves the at-home treatment thesis is violently disrupting the legacy 'wait-and-see' or in-office procedure paradigm.
By achieving trailing twelve-month revenue of $42.3 million, Pelthos unlocked the condition to potentially draw an additional $10 million from the Horizon facility, extending the cash runway ahead of 2027 pipeline launches.
🐻 Bear Case
Rapid revenue growth triggered $5.3 million in non-recurring sales milestones, driving SG&A to $27.7 million. At the current burn rate, the $24.2 million cash balance is tight, and the additional $10 million Horizon tranche is subject to lender discretion, not guaranteed.
A $0.9 million write-off of API inventory for failing quality control specifications introduces execution risk. While management says the procedural cause is addressed, this contradicts the narrative of a seamless, highly efficient supply chain.
⚖️ Verdict: 🟢
Bullish. The commercial execution on Zelsuvmi is undeniable, with 45% QoQ revenue growth. If management can control SG&A and fully resolve the API manufacturing hiccup, the operational leverage heading into the 2027 Xepi/Xeglyze launches is massive.
Key Themes
Zelsuvmi Volume and Breadth Accelerating
Zelsuvmi's market adoption is Accelerating aggressively. Q2 saw 11,925 units dispensed by 4,571 unique prescribers, up 48% from 8,084 units in Q1. The momentum continued post-quarter, with over 4,200 units dispensed in July alone (implying a >12,600 Q3 run rate). The product's innovation as the first at-home FDA-approved treatment for molluscum contagiosum is fundamentally changing pediatric and dermatological workflows.
Pipeline Synergies Drive Commercial Strategy
Pelthos is positioning to heavily leverage its 67-territory commercial footprint. The planned Q1 2027 launch of Xepi (impetigo) and Q3 2027 launch of Xeglyze (head lice) precisely target the exact same pediatric and dermatology call points as Zelsuvmi. This allows the company to stack revenue streams with minimal incremental SG&A overhead in the future.
Improving Underlying Operating Leverage
Stable. While GAAP Net Loss remained heavy at $(23.4) million, this was muddied by a $(3.7) million fair value adjustment on convertible debt and $5.3 million in one-time sales milestones. Adjusted EBITDA actually improved sequentially to $(5.7) million from $(8.0) million, proving that underlying operating leverage is beginning to emerge as revenue scales.
API Manufacturing Write-Off Contradicts IP Moat Narrative
Management previously touted its 'broad IP moat' and in-house API manufacturing superiority. However, Q2 COGS included a $0.9 million write-off for commercial API inventory that failed in-process quality control. While the company claims the underlying procedural cause was addressed, this signals early manufacturing growing pains that could threaten margins if not permanently fixed.
Cash Runway Reliant on Lender Discretion
The company's cash balance sits at $24.2 million. While Pelthos achieved the $42.3 million TTM revenue hurdle required to access an additional $10 million from its Horizon term loan, the release notes this access remains 'subject to the lender's discretion.' If the lender balks or delays, the company will have a very tight cash runway heading into 2027 pipeline launch pre-commercialization activities.
SG&A Spike Eclipses Revenue Gains
Accelerating SG&A growth completely absorbed Q2's revenue outperformance. SG&A jumped 31% QoQ to $27.7 million (up $6.6M). Although $5.3 million was due to one-time sales-based milestones, it highlights a structural concern: as the company successfully hits revenue targets, milestone obligations and royalty burdens ($6.0M total increase in Q2) will continue to aggressively tax cash flows.
Other KPIs
Accelerating improvement. Adjusted EBITDA loss narrowed from $(8.0) million in Q1 2026. This adds back $2.8 million in stock-based compensation, $2.3 million in inventory step-up, $3.7 million in debt fair value change, and the $5.3 million non-recurring milestone, showing the core business is inching closer to breakeven.
Decelerating margin profile temporarily. Rose sharply from $1.7 million in Q1 2026, largely driven by a $0.9 million API inventory write-off and $2.3 million in non-cash inventory valuation step-up related to the 2025 merger.
Up 43% from $10.9 million in Q1 2026. While license revenue dipped slightly ($183K vs $241K), the sheer volume of Zelsuvmi product sales thoroughly dominated the top-line performance.
Guidance
Stable. The commercial launch of Xepi for impetigo remains on track for the first quarter of 2027, maintaining the company's timeline to expand its dermatological footprint.
Stable. The anticipated commercial launch of Xeglyze for head lice is scheduled for the third quarter of 2027, continuing the sequential rollout of the acquired pipeline.
Accelerating. While management did not provide explicit full-year revenue guidance, the disclosure of >4,200 units in July implies a Q3 run rate easily exceeding 12,600 units, indicating continued sequential growth.
Key Questions
Horizon Facility Discretion
You noted that you met the $42.3M TTM revenue threshold for the additional $10M Horizon facility tranche, but it remains 'subject to lender's discretion.' What specific operational or financial milestones is the lender requiring to formally greenlight these funds?
Future Milestone Payments
Q2 included $5.3M in non-recurring sales-based milestones. What is the schedule and magnitude of the next tranches of sales-based milestones, and how will they impact cash burn in H2 2026?
Gross-to-Net (GTN) Evolution
In Q1 you indicated GTN was 29.1% but guided to a mid-30% range due to potential new payer contracts. Where did GTN settle in Q2, and what is the steady-state expectation for the remainder of 2026?
API Quality Control Remediation
Can you provide more detail on the out-of-specification API that led to the $0.9M write-off? Are there any downstream impacts to finished goods supply, and how has the testing procedure been permanently modified?